Visiting Professors and Guest Lecturers DEPARTMENT OF UROLOGY 2021 ZIMSKIND VISITING PROFESSOR MARCH 3 & 4, 2021 Stephanie Kielb, MD Our distinguished 2021 Zimskind Virtual Visiting professor was Dr. Stephanie Kielb. Dr. Kielb is Professor of Urology, Medical Education and Obstetrics and Gynecology at Northwestern University Feinberg School of Medicine, Chicago. Dr. Kielb is a board-certified urologist with a subspecialty certification in female pelvic medicine and reconstructive surgery. She is a professor of urology, medical education, and obstetrics and gynecology at Northwestern University Feinberg School of Medicine and the Division Chief of Reconstructive Urology, Neurourology, and Pelvic Medicine at Northwestern Medicine. She has been the residency program director in the Department of Urology since 2007 and sits on the Northwestern University McGaw Graduate Medical Education Committee. She is member of the ACGME Residency Committee for Urology and an assistant editor for the Journal of Urology. Dr. Kielb is a recognized expert in voiding dysfunction and incontinence, pelvic organ prolapse, neurourology, and congenital urology. She is the urologic director of the multi-disciplinary adult spina bifida clinic at Shirley Ryan Ability Lab (the number 1 rated rehabilitation hospital in the country), sits on the Shirley Ryan Ability Lab Medical Advisory Board and serves as a consulting physician there. Dr. Kielb is also the medical director of the Northwestern Medicine Transitional Adult Congenital Genitourinary Clinic (TRAC), a multispecialty clinic for patients with a variety of conditions including spina bifida, bladder and cloacal exstrophy, epispadias, anorectal malformations and many others. She is a founding member of the American Urological Association Working Group on Congenitalism and has published extensively on the needs and outcomes of this patient population.
Dr. Kielb is also committed to global health outreach, serving as mission leader and sitting on the medical director board of the International Organization for Women and Development, a charity devoted to obstetric fistula repair and medical education in Kigali, Rwanda since 2012. We were pleased to offer this CME approved program virtually in March of 2021. 2021 DAVID M. DAVIS VISITING PROFESSOR JUNE 18, 2021 Colin P.N. Dinney, MD, W.A. “Tex” & D. Moncrief, Jr. Distinguished Chair in Urology, University of Texas MD Anderson Cancer Center Houston, Texas After skipping 2020 due to the pandemic, we were pleased to offer the 2021 David M. Davis Visiting Professor in a virtual format with Dr. Colin Dinney. Dr. Dinney is Professor and Chairman of Urology University of Texas MD Anderson Cancer Center. He served as the Director of MD Anderson’s Bladder Cancer SPORE from 2001-2019 and maintains an active clinical practice specializing in bladder cancer and a research laboratory focused on understanding the biology of bladder cancer metastases and on the development of novel therapy for bladder cancer. His group played a pioneering role in developing preclinical models of spontaneous bladder cancer metastasis and used these models to identify the mechanisms regulating metastasis and for preclinical therapeutic studies. His group developed intravesical nadofaragene firadenovec (adenoviral mediated interferon-α gene therapy) for the treatment of BCG unresponsive nonmuscle invasive bladder cancer. A Phase 3 trial was conducted by the SUO-CTC (Society of Urologic Oncology Clinical Trials Consortium) and the drug is currently working through the FDA approval process with Jefferson contributing a significant number of patients on that trial. Currently his laboratory is working to improve interferon gene therapy by identifying biomarkers that predict sensitivity or resistance, by testing novel vectors that might improve transfection efficiency and activity, and by evaluating novel combination strategies. Dr. Dinney served on the Society of Urologic Oncology Executive Committee and was the Founding President of the SUO’s Clinical Trial Consortium and is the current Chair of the SUO CTC Bladder Cancer Committee. Dr. Dinney is the SPORE’s Liason to SWOG’s GU Executive Committee. He is also a former member of the National Institutes of Health, Genitourinary Steering Committee, and served as the Urology Chair for the Bladder Cancer Task Force from 2016-2019. Dr. Dinney presented two lectures “Neoadjuvant Therapy for MIBC in the Genomics Era” and “Therapy for High-risk NMIBC”. His visiting professorship also included residents presentation reviewing the diagnosis and management of Urology cases.
Chief residents Drs. Tom Hardacker, Chris Caputo and MJ Counsilman posing with our “vitual” 2021 DM Davis visiting professor Dr. Colin Dinney (see page 65 for details on this photo). 44
Year in Review
